AlphaStar Capital Management LLC Buys Shares of 16,817 Pfizer Inc. (NYSE:PFE)

AlphaStar Capital Management LLC bought a new stake in Pfizer Inc. (NYSE:PFEFree Report) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 16,817 shares of the biopharmaceutical company’s stock, valued at approximately $484,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Briaud Financial Planning Inc acquired a new position in shares of Pfizer during the 3rd quarter valued at about $30,000. GoalVest Advisory LLC increased its stake in shares of Pfizer by 304.9% during the 4th quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock valued at $31,000 after acquiring an additional 811 shares during the last quarter. Mizuho Securities Co. Ltd. acquired a new stake in Pfizer during the 3rd quarter worth approximately $34,000. VisionPoint Advisory Group LLC increased its position in Pfizer by 52,350.0% during the 3rd quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock worth $35,000 after purchasing an additional 1,047 shares in the last quarter. Finally, Tennessee Valley Asset Management Partners acquired a new stake in Pfizer during the 4th quarter worth approximately $36,000. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

PFE has been the subject of a number of research analyst reports. Morgan Stanley increased their target price on shares of Pfizer from $28.00 to $29.00 and gave the stock an “equal weight” rating in a research report on Thursday, May 2nd. Cantor Fitzgerald reissued an “overweight” rating and set a $45.00 target price on shares of Pfizer in a research report on Monday, April 15th. Argus downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Guggenheim initiated coverage on shares of Pfizer in a research report on Friday, February 23rd. They set a “buy” rating and a $36.00 target price for the company. Finally, BMO Capital Markets reissued an “outperform” rating and set a $36.00 target price (up previously from $33.00) on shares of Pfizer in a research report on Thursday, May 2nd. Ten research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from, the stock presently has an average rating of “Hold” and an average price target of $35.86.

Check Out Our Latest Stock Analysis on PFE

Pfizer Price Performance

Shares of PFE stock traded up $0.36 during mid-day trading on Monday, hitting $28.37. 21,057,018 shares of the stock traded hands, compared to its average volume of 43,144,797. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.78 and a current ratio of 1.05. The firm has a market cap of $160.76 billion, a price-to-earnings ratio of -476.42, a price-to-earnings-growth ratio of 1.18 and a beta of 0.63. The company’s 50-day simple moving average is $27.00 and its 200-day simple moving average is $28.08. Pfizer Inc. has a twelve month low of $25.20 and a twelve month high of $40.37.

Pfizer (NYSE:PFEGet Free Report) last issued its earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.56 by $0.26. The business had revenue of $14.88 billion for the quarter, compared to analysts’ expectations of $13.87 billion. Pfizer had a positive return on equity of 8.64% and a negative net margin of 0.56%. The company’s quarterly revenue was down 19.5% on a year-over-year basis. During the same period in the previous year, the firm posted $1.23 EPS. As a group, equities research analysts expect that Pfizer Inc. will post 2.39 earnings per share for the current year.

Pfizer Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, June 14th. Investors of record on Friday, May 10th will be issued a $0.42 dividend. This represents a $1.68 dividend on an annualized basis and a dividend yield of 5.92%. The ex-dividend date of this dividend is Thursday, May 9th. Pfizer’s payout ratio is -2,799.53%.

Pfizer Profile

(Free Report)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

See Also

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with's FREE daily email newsletter.